Potential role of retina as a biomarker for progression of Parkinson's disease

International Journal of Ophthalmology

Volumn 4, Issue 4, 2011, Pages 433-438

  Tian, Tian ^a   Zhu, Xiao Hua ^b   Liu, Yun Hai ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Optical coherence tomography; Parkinson disease; Retinal nerve fiber layer thickness

Indexed keywords

EID: 84897585026     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2011.04.21     Document Type: Review

References (51)

1. Spillantini MG, Schmidt ML, Lee V.M., Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997; 388(6645):839-840.
2. Seibyl JP, Marek KL, Quinlan D, Sheff K., Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B. Smith EO, Charney DS, Hoffer PB, Innis RB. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995; 38(4):589-598.
3. Brücke T., Asenbaum S, Pirker W., Djamshidian S, Wenger S, Wöber C, Müller C, Podreka I. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997; 50(1):9-24.
4. Péran P., Cherubini A, Assogna F., Piras F, Quattrocchi C, Peppe A., Celsis P, Rascol O, Démonet JF, Stefani A., Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain. 2010; 133(11):3423-3433.
5. Schuman JS, Hee MR, Arya A.V., Pedut-Kloizman T, Puliafito CA, Fujimoto J.G., Swanson EA Optical coherence tomography: a new tool for glaucoma diagnosis. Curr Opin Ophthalmol. 1995; 6(2):89-95.
6. Schuman JS, Hee MR, Puliafito C.A., Wong C., Pedut-Kloizman T, Lin CP, Hertzmark E, Izatt J.A., Swanson EA, Fujimoto JG Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol. 1995; 113(5):586-596.
7. Puliafito CA, Hee MR, Lin C.P., Reichel E., Schuman JS, Duker JS, Izatt JA, Swanson E.A., Fujimoto JG Imaging of macular diseases with optical coherence tomography. Ophthalmology. 1995; 102(2):217-229.
8. Djamgoz MB, Hankins MW, Hirano J, Archer SN Neurobiology of retinal dopamine in relation to degenerative states of the tissue. Vision Res. 1997; 37(24):3509-3529.
9. Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest Ophthalmol Vis Sci. 1990; 31(11):473-2475.
10. Nguyen-Legros J. Functional neuroarchitecture of the retina: hypothesis on the dysfunction of retinal dopaminergic circuitry in Parkinson's disease. Surg Radiol Anat. 1988; 10:137-144.
11. Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M., Glover A, Onofrj M. Systemic 1-methyl, 4-phenyl, 1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci. 1988; 43(3):255-262.
12. Hutton JT, Morris JL Vision in Parkinson's disease. Adv Neurol. 2001; 86:279-288.
13. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci. 1990; 13(7):296-302.
14. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin. 2003; 21(3):709-728.
15. Rodnitzky RL. Visual dysfunction in Parkinson's disease. Clin Neurosci. 1998; 5(2):102-106.
16. Dyer RS, Howell WE, MacPhail RC Dopamine depletion slows retinal transmission. Exp Neurol. 1981; 71(2):326-340.
17. Onofrj M, Bodis-Wollner I. Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann Neurol. 1982; 11(5):484-490.
18. Bodis-Wollner I., Yahr MD. Measurements of visual evoked potentials in Parkinson's disease. Brain. 1978; 101(4):661-671.
19. Barbato L, Rinalduzzi S, Laurenti M., Ruggieri S, Accornero N. Col or VEPs in Parkinson's disease. Electroencephalogr Clin Neurophysiol. 1994; 92(2):169-172.
20. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology. 1992; 42(4):887-890.
21. Tagliati M, Bodis-Wollner I, Kovanecz I., Stanzione P. Spatial frequency tuning of the monkey pattern ERG depends on D2 receptor-linked action of dopamine. Vision Res. 1994; 34(16):2051-2057.
22. Tagliati M, Bodis-Wollner I, Yahr MD. The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalogr Clin Neurophysiol. 1996; 100(1):1-11.
23. Bodis-Wollner I., Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vision Res. 1998; 38(10):1479-1487.
24. Tatton WG, Kwan MM, Verrier M.C., Seniuk NA, Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells. Brain Res. 1990; 527(1):21-31.
25. Kramer S, Potts A, Mangnall Y. Dopamine: a retinal neurotransmitter. II. Autoradiographic localization of H3-dopamine in the retina. Invest Ophthalmol. 1971; 10(6):617-624.
26. Bodis-Wollner I., Tagliati M. The visual system in Parkinson's disease. Adv Neurol. 1993; 60:390-394.
27. Frederick J, Rayborn M, Laties A., Lam D, Hollyfield J. Dopaminergic neurons in the human retina. J Comp Neurol. 1982; 210(1):65-79.
28. Huang D, Swanson EA, Lin C.P., Schuman JS, Stinson WG, Chang W, Hee M.R., Flotte T., Gregory K, Puliafito CA, Fujimoto JG Optical coherence tomography. Science. 1991; 254(5035):1178-1181.
29. Ishikawa H, Stein DM, Wollstein G, Beaton S., Fujimoto JG, Schuman JS Macular segmentation with optical coherence tomography. Invest Ophthalmol Vis Sci. 2005; 46(6):2012-2017.
30. Ko TH, Fujimoto JG, Schuman J.S., Paunescu LA, Kowalevicz AM, Hartl I, Drexler W., Wollstein G, Ishikawa H, Duker JS Comparison of ultrahigh- and standard-resolution optical coherence tomography for imaging macular pathology. Ophthalmology. 2005; 112(11):1922.e1921-1915.
31. Sho K, Takahashi K, Fukuchi T., Matsumura M. Quantitative evaluation of ischemia-reperfusion injury by optical coherence tomography in the rat retina. Jpn J Ophthalmol. 2005; 49(2):109-113.
32. Li Q, Timmers AM, Hunter K, Gonzalez-Pola C, Lewin A.S., Reitze DH, Hauswirth WW Noninvasive imaging by optical coherence tomography to monitor retinal degeneration in the mouse. Invest Ophthalmol Vis Sci. 2001; 42(12):2981-2989.
33. Horio N, Kachi S, Hori K., Okamoto Y, Yamamoto E, Terasaki H., Miyake Y. Progressive change of optical coherence tomography scans in retinal degeneration slow mice. Arch Ophthalmol. 2001; 119(9):1329-1332.
34. Kanamori A, Escano MF, Eno A, Nakamura M., Maeda H, Seya R, Ishibashi K., Negi A. Evaluation of the effect of aging on retinal nerve fiber layer thickness measured by optical coherence tomography. Ophthalmologica. 2003; 17(4):273-278.
35. Blumenthal EZ, Williams JM, Weinreb R.N., Girkin CA, Berry CC, Zangwill LM Reproducibility of nerve fiber layer thickness measurements by use of optical coherence tomography. Ophthalmology. 2000; 107(12):2278-2282.
36. Budenz DL, Chang RT, Huang X, Knighton R.W., Tielsch JM Reproducibility of retinal nerve fiber thickness measurements using the stratus OCT in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2005; 46(7):2440-2443.
37. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 2004; 44(24):2793-2797.
38. El Beltagi T.A., Bowd C, Boden C., Amini P, Sample PA, Zangwill L.M., Weinreb RN Retinal nerve fiber layer thickness measured with optical coherence tomography is related to visual function in glaucomatous eyes. Ophthalmology. 2003; 110(11):2185-2191.
39. Altintaş O, Işeri P, Ozkan B, Caǧlar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol. 2008; 116(2):137-146.
40. Hajee ME, March WF, Lazzaro D.R., Wolintz AH, Shrier EM, Glazman S, Bodis-Wollner IG. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol. 2009; 127(6):737-741.
41. Wojtkowski M, Srinivasan V, Fujimoto J.G., Ko T., Schuman JS, Kowalczyk A, Duker JS Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology. 2005; 112(10):1734-1746.
42. Aaker GD, Myung JS, Ehrlich J.R., Mohammed M., Henchcliffe C, Kiss S. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol. 2010; 4:1427-1432.
43. Moschos MM, Tagaris G, Markopoulos I., Margetis I, Tsapakis S, Kanakis M., Koutsandrea C. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur J Ophthalmol. 2011; 21(1):24-29.
44. Zhang X, Rojas JC, Gonzalez-Lima F. Methylene blue prevents neurodegeneration caused by rotenone in the retina. Neurotox Res. 2006; 9(1):47-57.
45. Archibald NK, Clarke MP, Mosimann U.P., Burn DJ Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord. 2011; 17(6):431-436.
46. Drexler W, Fujimoto JG State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res. 2008; 27(1):45-88.
47. de Boer J.F., Cense B, Park B.H., Pierce MC, Tearney GJ, Bouma BE Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. Opt Lett. 2003; 28(21):2067-2069.
48. Choma M, Sarunic M, Yang C, Izatt J. Sensitivity advantage of swept source and Fourier domain optical coherence tomography. Opt Express. 2003; 11(18):2183-2189.
49. Leitgeb R, Hitzenberger C, Fercher A. Performance of fourier domain vs time domain optical coherence tomography. Opt Express. 2003; 11(8):889-894.
50. Jiao S, Knighton R, Huang X., Gregori G, Puliafito C. Simultaneous acquisition of sectional and fundus ophthalmic images with spectral-domain optical coherence tomography. Opt Express. 2005; 13(2):444-452.
51. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J Neurol. 2002; 249(Suppl 3)(III/1-5)